Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early clinical outcomes as it strengthens its position in Australia’s emerging psychedelic medicine market.
Key highlights
- FY26 revenue reached approximately $4.3 million, representing growth of around 210% over FY25, driven by expanding clinic activity and insurer-funded patient demand.
- Victoria is now online, with the Mornington Peninsula Empax clinic successfully commencing patient treatments, giving Emyria operations across three states.
- New South Wales is next, with the Sydney (Kingswood) clinic on track to open in Q3 2026. The company has already trained 25 therapists and six psychiatrists, adding to a national workforce of more than 100 clinicians.
- Early clinical data is encouraging. The first ten patients treated for treatment-resistant depression showed improvements across all four standard mental health measures, with average depression scores falling from 16.8 to 10.0.
- Recent TGA changes that broaden the range of clinicians able to participate in psychedelic-assisted psychotherapy should make it easier for providers like Emyria to recruit staff, increase treatment capacity and improve patient access.
- Emyria has also launched its Global Partnership Program, creating a new sponsor-funded services business alongside its clinical operations.
The quarterly update also comes as global pharmaceutical companies continue to validate the psychedelic sector through major acquisitions, with both Eli Lilly and AbbVie announcing multi-billion-dollar investments in psychedelic drug development during the quarter.
With clinics now operating in Western Australia, Queensland and Victoria, New South Wales set to open shortly, expanding insurer reimbursement pathways and growing clinical evidence supporting treatment-resistant depression, Emyria continues to execute on one of Australia’s most advanced psychedelic medicine delivery strategies.
As Australia’s regulatory framework matures, the focus is rapidly shifting from proving the science to building the clinical infrastructure capable of delivering these therapies at scale. For companies like Emyria, success will increasingly depend on expanding clinical capacity, training qualified practitioners and making these therapies accessible to more patients across the country.
